![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Says All Off-Label Communications Can Fall Within Regulatory Purview
FDA Says All Off-Label Communications Can Fall Within Regulatory Purview
![](https://www.fdanews.com/ext/resources/test/Drug-Images/Pharma-Labels.gif?t=1433873566&width=430)
January 24, 2017
The First Amendment does not preclude drugmakers from FDA’s oversight of off-label communication even if what they say is truthful, the agency said.
The agency has the authority to regulate all off-label communication to ensure unapproved drugs do not reach the market, according to an FDA memo.
The FDA cannot explicitly restrict communication on off-label uses, but it has the power to regulate the introduction of unapproved or misbranded drugs and a company’s promotions might be relevant to enforcement.
Upcoming Events
-
21Oct